SINGAPORE: The Ministry of Health and the expert committee on COVID-19 vaccinations are now conducting investigations on the efficiency and safety of Moderna and Pfizer’s BioNTech vaccines in children.
From the age of six months up to four year olds, the trial will evaluate the use of the aforementioned vaccines.
The US Centers for Disease Control and Prevention recommended COVID-19 immunizations for children as young as six months on Saturday, paving the way for a statewide distribution next week. After a group of experts voted to recommend COVID-19 vaccinations for such youngsters, the CDC took action.
Moderna’s vaccination for children aged six months to five years and Pfizer-vaccine BioNTech’s for children aged six months to four years were both approved by the US Food and Drug Administration on Friday. In the United States, Pfizer-vaccine BioNTech is already approved for children over the age of five.
Last December 27, the Ministry of Health initiated a vaccination campaign for children aged five to eleven.
Related Posts
The Health Sciences Authority (HSA) noted in a January update that no major side effects had been reported for persons in that age range who had received their vaccines as of the end of December.
Everyone who is eligible for COVID-19 vaccine, regardless of age, can come in for their primary vaccination series and booster doses any day of the week before 7 p.m.
According to the MOH website, no appointment is required.
Children aged five to eleven can visit any paediatric vaccination center with their parents or guardians to receive their vaccine doses. Those aged 12 to 17 can get the Pfizer-BioNTech vaccine at any immunization center that offers it.
As of Sunday, 92% of the population has finished the entire COVID-19 vaccine regimen. Approximately 77% of people have received their booster doses.
